#### You are editing your previous response.

Be careful when sharing the URL of this page, because it will allow others to also edit your response.

Fill out a new response.

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs.

b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Eysen CONS and M J Med URL: <u>h</u> doi: 1(	otion): coach G, CONSORT-EHEALTH Group DRT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based cobile Health Interventions Internet Res 2011;13(4):e126 <a href="http://www.jmir.org/2011/4/e126/">http://www.jmir.org/2011/4/e126/</a> .2196/jmir.1923 22209829
* Requ	red
Your r	
First La	van Rosmalen-Noo
Univer	ry Affiliation (short), City, Country * ity of Toronto, Toronto, Canada oud University Medi
Your e	-mail address *
abc@c	<u>mail.com</u>
karin	vanrosmalen-nooije
Youn the ir	the (draft) title of your manuscript.  g people, Adult worries: a randomised feasibility study of ternet-based self-support method "Feel the ViBe" for scents and young adults exposed to family violence.
	Preparation Status/Stage * th stage in your article preparation are you currently (at the time you fill in this form)
O no	submitted yet - in early draft status
• no	submitted yet - in late draft status, just before submission
O sul	mitted to a journal but not reviewed yet
O sul	mitted to a journal and after receiving initial reviewer comments
O sul	mitted to a journal and accepted, but not published yet
O pu	lished
O 0+l	er.
Otl	···

<ul><li>Journal of</li></ul>	nitted yet / unclear where I will submit this
	of Medical Internet Research (JMIR)
Other:	
Manusarint	tracking number *
If this is a JM ms tracking I login as auth	AIR submission, please provide the manuscript tracking number under "other" (The number can be found in the submission acknowledgement email, or when you nor in JMIR. If the paper is already published in JMIR, then the ms tracking number git number at the end of the DOI, to be found at the bottom of each published
o no ms nu	umber (yet) / not (yet) submitted to / published in JMIR
Other:	
TITLE /	AND ABSTRACT
title	LE: Identification as a randomized trial in the
,	our paper address CONSORT item 1a? *  title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason ")
○ yes	
Other: R	andomised feasibility st
•	fy the mode of delivery in the title
game" in the based" only i "computer-ba context of "v groups". Con	mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internetif Intervention includes non-web-based Internet components (e.g. email), use ased" or "electronic" only if offline products are used. Use "virtual" only in the rirtual reality" (3-D worlds). Use "online" only in the context of "online support implement or substitute product names with broader terms for the class of products obile" or "smart phone" instead of "iphone"), especially if the application runs on
game" in the based" only i "computer-ba context of "v groups". Con (such as "mo	mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internetif Intervention includes non-web-based Internet components (e.g. email), use ased" or "electronic" only if offline products are used. Use "virtual" only in the rirtual reality" (3-D worlds). Use "online" only in the context of "online support implement or substitute product names with broader terms for the class of products obile" or "smart phone" instead of "iphone"), especially if the application runs on
game" in the based" only i "computer-ba context of "v groups". Con (such as "mo different plat	mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internetif Intervention includes non-web-based Internet components (e.g. email), use ased" or "electronic" only if offline products are used. Use "virtual" only in the rirtual reality" (3-D worlds). Use "online" only in the context of "online support implement or substitute product names with broader terms for the class of products obile" or "smart phone" instead of "iphone"), especially if the application runs on thorms.

complexity of findings we measures according to Bo primary outcomes as interdescribed in the study pro	decided wen (20 nded. Ti tocol. T	o do just orming I to inc 009) w ne stud herefo	stice the s lude hile s dy wa re, as	to bostudy feas still in the st	y and the ibility noluding the erformed as	
a RCT and a feasibility stu						
<b>1a-ii) Non-web-based co</b> Mention non-web-based co telephone support").	-		-			
	1 :	2 3	4	5		
subitem not at all important		) ()	0	0	essential	
_						
his" to indicate direct quote	ctions fres	rom m your n	anus nanus	scrip	ot), or elaborate	uotes in quotation marks "like on this item by providing n is not applicable/relevant
Although the safety protoc in case of emergency, we is not a vital part of the inte	did not	includ	e this			
	or targ	_	-			
Mention primary condition of Diabetes") Example: A Web-	or targe -based	and Mo	obile	Inter	rvention with Te	for children with Type I elephone Support for Children
Mention primary condition on Diabetes") Example: A Web-	or targe -based a omized (	and Mo	obile lled 1	Inter	rvention with Te	
1a-iii) Primary condition of Mention primary condition of Diabetes") Example: A Webwith Type I Diabetes: Rando	or targe -based a omized (	and Mo Contro 2 3	obile Iled 7 4	Inter Frial 5	rvention with Te	

## 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

### 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Adolescents and young adults aged 12-25 exposed to family violence, were randomized in an intervention group (access to FtV + usual care), and a control group (minimally enhanced usual care)."

#### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	I	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 1b-ii?

b-iii) Open vs. closed, very he METHODS section of Mention how participants or from a clinic or a closed ourely web-based trial, or the assessment). Clearly say in	f the A were re l online here w	ABST ecrui e use ere f	TRAC ted ( er gro ace-	CT onlir oup ( to-fa	ne vs close ce c	. offline), e.g ed usergroup omponents (	, from an o trial), and o as part of t	pen access clarify if thi he interven	s website s was a tion or for
n web-based trials). Note: linical trial in which both t dministered. To avoid con estead of "open", as "oper an self-enrol). (Note: Only enformation is missing from	the res nfusior n" in we report	earc n, us eb-ba t in tl	hers e "bli ased he al	and ndeo trial ostra	parti d" or s usu ct w	icipants know "unblinded" ually refers to hat the main	v which treated in dicated of the condition of the condit	atment is b I the level c ess" (i.e. pa	eing of blinding articipants
	1	2	3	4	5				
ubitem not at all importar	nt (	0	0	0	0	essential			
Does your paper address Copy and paste relevant se narks "like this" to indicate providing additional inform	ections e direc nation	fror t quo not i	n the	e ma from	you	r manuscript	), or elabora	ate on this	
Copy and paste relevant senarks "like this" to indicate	ections e direct nation of or study istered	fror t quo not ii	n the	e ma from ms,	you or b	r manuscript riefly explair	), or elabora	ate on this	
Copy and paste relevant so narks "like this" to indicate providing additional inform pplicable/relevant for you Yes, participants self-reg	ections e direct nation of or study istered	fror t quo not ii	n the	e ma from ms,	you or b	r manuscript riefly explair	), or elabora	ate on this	
Copy and paste relevant so narks "like this" to indicate providing additional inform pplicable/relevant for you Yes, participants self-reg	ections e direct nation of or study istered	fror t quo not ii	n the	e ma from e ms,	you or b	r manuscript riefly explair	), or elabora	ate on this	
Copy and paste relevant senarks "like this" to indicate providing additional inform applicable/relevant for you.  Yes, participants self-reg components are web-base.	ections e direction of action of or study istered sed	fror t quo not in y I, sel	n the	e ma from e ms, sesse	your or b	r manuscript riefly explain nd all	), or elabora why the ite	ate on this	
copy and paste relevant seconarks "like this" to indicate providing additional information pplicable/relevant for you.  Yes, participants self-reg components are web-based being the provided and the provided primary/secondary outcomes and pasteries.	in abs	s from t quo not it quo not it quo y I, sell strac rolle ence (No	m the motes in the fraction of the motes in	e ma from ms, ms, seesse seesse rics, nly ro	conta	r manuscript riefly explain ain use data n each group over time, nu t in the abstr	, the use/upmber of logact what the	ptake of the gins etc.), ir e main pap	e n addition er is
copy and paste relevant secondrical second	in abs	s from t quo not it quo not it quo y I, sell I, sell issin	m the motes in the fraction of the motes in	ust of seess	contacted in the contac	r manuscript riefly explain ain use data n each group over time, nu t in the abstr	, the use/upmber of logact what the	ptake of the gins etc.), ir e main pap	e n addition er is

applicable/relevant for your study

Yes,										
						<u> </u>				
1b-v) CONCLUSION Conclusions/Discustrial is negative (prowhether negative report in the abstrational body of text,	ussions in absimary outcor esults are attact what the r consider add	stract for me not of cributab main pa ling it)	or neg chang le to l aper is	ed), a ed), a ack of repor	trials: Disc nd the inte f uptake an	uss the prvention value of the discussions of the d	rimary was no s reas	ot used ons. (N	, discus ote: Onl	s y
	1	2	3 4	1 5						
subitem not at all i	mportant C	) ()	0 (		essential					
ipplicable/relevan	t for your stu				oriefly expl			11 13 110		
The sample size however, includir sample size of 17 participants: "As we included reach the calcula IES were found."	was reacheding only comp 7 participants complete meated sample s	for par lete me instead asurem ize (n=	easure d of th nents of 18). N	ments e nee only, w lo cha	nd use, s lead to a ded 18 ve did not nges on th	e		1113110		
The sample size however, includir sample size of 17 participants: "As we included reach the calcula IES were found. results."  INTRODUCTOR  2a) In INT  explanation	was reacheding only comp 7 participants complete mented sample s SCL-90 DEP  CTION  RODUCTON  On of rain	for par lete me instead asurem ize (n= and AN	easured of the sents of 18). Now Show	ments e nee only, who chap ow pro	nd use, is lead to a ded 18 we did not nges on thomising	~				d
The sample size however, includir sample size of 17 participants: "As we included reach the calcula IES were found. results."	was reached by only composite mented samples of the type of ty	for parlete me instead asurem ize (n= and A	N: Sale	ments e nee only, who chan ow pro	entific  tion that is er health cantion, e.g.,	back  s object of are prograte being mo	f the sam? In	ouncestudy: intended	d and	as ther
The sample size however, includir sample size of 17 participants: "As we included reach the calcula IES were found. results."  INTRODUCE  2a) In INT  explanation  2a-i) Problem and Describe the problem and Describe the problem and Describe interventions, replanter properties.	was reached by only composite mented sample services and the type of type of the type of the type of t	for parlete me instead asurem ize (n= and A	N: Sale	SCIE	entific  tion that is er health cantion, e.g.,	back  s object of are prograte being mo	f the sam? In	ouncestudy: intended	d and	as ther
The sample size however, includir sample size of 17 participants: "As we included reach the calcula IES were found. results."  INTRODUCE  2a) In INT  explanation  2a-i) Problem and Describe the pr	was reached ag only composite of participants complete mented sample sented sample sented sample of the type of type of the type of type of the type of the type of the type of type o	for parlete me instead asuremize (n= and Afficial Afficia	N: Cale	Scie	end use, is lead to a ded 18 we did not inges on the omising entific tion that is er health contion, e.g., lons? (Note:	back s object of are progrebeing models are Details a	f the sam? In	ouncestudy: intended	d and	as ther

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like
this" to indicate direct quotes from your manuscript), or elaborate on this item by providing
additional information not in the ms, or briefly explain why the item is not applicable/relevant
for your study

#### Yes

"Feel the ViBe is a freely-available, internet-based self-support method for adolescents and young adults exposed to FV [18, 19] with three main goals: to provide information, to offer (peer) support and to lower the threshold to regular healthcare services."

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Both rationale for design and background were included	^
	<u> </u>

## 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Objective/ Research Question "Is Feel the ViBe an feasible and effective way of reaching and delivering healthcare to adolescents and young adults exposed to family violence?".	^
to family violence: .	<b>~</b>

#### **METHODS**

## 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were randomised in two parallel groups with a 1:1 allocation ratio: an intervention group, having access to "Feel the ViBe" + usual care (UC), and a control group, having access to minimally enhanced usual care (mEUC), both of which have been extensively described in the study protocol of FtV[19].

## 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

· · · · · · · · · · · · · · · · · · ·	
All changes were reported under a separate heading	^
	<b>\</b>


#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing



yes Computer literacy is assumed	^
	<b>\</b>

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple

	CI C (	ısed			logi /pre	event these.
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
this to indicate direct quotes additional information not in for your study  Yes, these are all clarified i	tions s fro the in the	m yo ms, o	m the our m or br	e ma nanu: iefly	expl:	cript (include quotes in quotation marks "like ot), or elaborate on this item by providing ain why the item is not applicable/relevant
ViBe: DOI: 10.1186/1471-2		-13-2	226)			
in the informed consent prod	ruitn cedu ), as	nent. res ( this	Spe e.g., infor esult	cify   publ mati	now ish tl on m	participants were briefed for recruitment ar he informed consent documentation as nay have an effect on user self-selection,
		_				
subitem not at all important	0	0	0	0		essential
Does your paper address s Copy and paste relevant sections to indicate direct quotes	<b>subi</b> tions	<b>tem</b> s from	<b>4a-i</b> m the	i <b>ii?</b> e ma	nusc	essential  cript (include quotes in quotation marks "like ot), or elaborate on this item by providing ain why the item is not applicable/relevant

#### Does your paper address CONSORT subitem 4b? \*

	only.		^
			<b>\</b>
4b-i) Report if outcomes v	vere (self-)assesse	d through online	questionnaires
Clearly report if outcomes w web-based trials) or otherwis		nrough online que	stionnaires (as common in
	1 2 3 4 5		
subitem not at all important	00000	) essential	
Does your paper address			
Copy and paste relevant sec this" to indicate direct quote:			
additional information not in			
for your study yes			
"All outcomes were self-as:	sessed through online	е	^
questionnaires"			
4b-ii) Report how instituti	onal affiliations are	displayed	
Report how institutional affil	iations are displayed	to potential partic	
and affiliations and the control of			olunteer rates, use, and
			scribe only if this may bias
reactions with regards to an	intervention.(Not a re	equired item — des	scribe only if this may bias
reactions with regards to an	1 2 3 4 5		scribe only if this may bias
reactions with regards to an results)	1 2 3 4 5	· ·	cribe only if this may bias
reactions with regards to an results)	1 2 3 4 5		cribe only if this may bias
reactions with regards to an results)	1 2 3 4 5	· ·	cribe only if this may bias
reactions with regards to an results) subitem not at all important	1 2 3 4 5	· ·	cribe only if this may bias
reactions with regards to an results)  subitem not at all important  Does your paper address so Copy and paste relevant sec	1 2 3 4 5  Subitem 4b-ii?  tions from the manus	essential script (include quo	otes in quotation marks "like
reactions with regards to an results)  subitem not at all important  Does your paper address so this to indicate direct quotes additional information not in	1 2 3 4 5  subitem 4b-ii? tions from the manus	essential script (include quo	otes in quotation marks "like on this item by providing
reactions with regards to an results)  subitem not at all important  Does your paper address so Copy and paste relevant sections to indicate direct quote additional information not in for your study	1 2 3 4 5  subitem 4b-ii? tions from the manuser from your manuscrithe ms, or briefly exp	essential script (include quo ipt), or elaborate o	otes in quotation marks "like on this item by providing
reactions with regards to an results)  subitem not at all important  Does your paper address so Copy and paste relevant sections to indicate direct quotes additional information not infor your study  We do not feel there is a bi	1 2 3 4 5  subitem 4b-ii? tions from the manuser the ms, or briefly expanses because of institute.	essential script (include quo ipt), or elaborate o blain why the item	otes in quotation marks "like on this item by providing
reactions with regards to an results)  subitem not at all important  Does your paper address so Copy and paste relevant sections to indicate direct quote additional information not in for your study	1 2 3 4 5  subitem 4b-ii? tions from the manuser the ms, or briefly expanses because of institute the ViBe is archived in	essential script (include quo ipt), or elaborate o blain why the item	otes in quotation marks "like on this item by providing
reactions with regards to an results)  subitem not at all important  Does your paper address so Copy and paste relevant sections to indicate direct quotes additional information not infor your study  We do not feel there is a bia affiliations, however, Feel to	1 2 3 4 5  subitem 4b-ii? tions from the manuser the ms, or briefly expanses because of institute the ViBe is archived in	essential script (include quo ipt), or elaborate o blain why the item	otes in quotation marks "like on this item by providing
reactions with regards to an results)  subitem not at all important  Does your paper address so this to indicate direct quotes additional information not infor your study  We do not feel there is a biaffiliations, however, Feel the results of the substitution of the	1 2 3 4 5  subitem 4b-ii? tions from the manuser the ms, or briefly expanses because of institute the ViBe is archived in	essential script (include quo ipt), or elaborate o blain why the item	otes in quotation marks "like on this item by providing

# 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

#### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All data on the content of Feel the ViBe en minimally enhanced usual care is described in detail in the study protocol: DOI: 10.1186/1471-2458-13-226)

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The development of Feel the ViBe is described in detail in the study protocol. This is de first version/evaluation of the intervention.

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the

- 4					
1	2	3	4	5	
0	0	0	0	0	essential
subi	tem	5-iii	?		
s fro	m yo	our m	nanu	scrip	ript (include quotes in quotation marks "like t), or elaborate on this item by providing ain why the item is not applicable/relevant
er al	l par	ticipa	ants t	finish	ed all
					<b>~</b>
0	0	0	0	0	essential
subi	tem	5-iv	?		
s fro	m yo	our m	nanu	scrip	ript (include quotes in quotation marks "like t), or elaborate on this item by providing ain why the item is not applicable/relevant
ed in ne, ii e and	the nterv	stud <sub>y</sub> iew j vide	y pro partion	toco cipan ential	I. Before ts were
					Ť
ure v shing ing f	<b>rided</b> the lowe	sour harts	d/or ce co s of t	provide, a	rce code, and/or providing viding flowcharts of the algorithms used and/or providing screenshots/screenlgorithms used. Replicability (i.e., other the study) is a hallmark of scientific
	subinations as from the sethod at the sethod	subitem etions from your the ms, or the ms, or the ms, or the ms and particular the ms, or the ms,	tions from the strom your man the ms, or brown the ms, or brown the reall participate and participate and provide rotocol: DOI: 1	subitem 5-iii?  Intions from the makes from your manuse the ms, or briefly seversion 1.0. Charter all participants the main grant participants are an	subitem 5-iii?  stions from the manuscips from your manuscrips the ms, or briefly explain the ms, or briefly explains a version 1.0. Changes for all participants finish heaning 24+2 weeks after the manuscips of the ms, or briefly explains from the manuscrips of the ms, or briefly explains and provide essential rotocol: DOI: 10.1186/1  by publishing the sour ware video, and/or provide in the source code, aling flowcharts of the alignment of the alignment of the alignment of the alignment of the manuscips of the alignment of the alignment of the alignment of the alignment of the manuscips of the alignment of the

Does your paper	address	subitem	5-v?
-----------------	---------	---------	------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Feel the ViBe as a whole was captured using Web Citation and the total intervention was archived. The CMS shows version history. Any data necessary for replicability can be provided by the authors.

#### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <a href="webcitation.org">webcitation.org</a>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Feel the ViBe as a whole was captured using Web Citation and the total intervention was archived. The CMS shows version history. Any data necessary for replicability can be provided by the authors. A powerpoint presentation showing screenshots has been made available for the readers.

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5 subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 5-vii? \*

	parameters eters (e.g., in mendations any, or was the	m your mms, or bridger, design protocol	doses" a	and optimal time user, e.g., regsed ad libitum.	e on the m is n	nis item by providing not applicable/relevant
his to indicate directed ditional information or your study  All available information is provided in detail of the company of	parameters eters (e.g., in	m your mms, or bridger, design protocol	doses" a	ipt), or elaborate plain why the ite communication and optimal time user, e.g., reg.	e on the m is n	nis item by providing not applicable/relevant
his to indicate directed distinguished by the following the following distribution of the follow	ation on the	m your m ms, or bri ory, design protocol	nanuscr iefly exp gn and o	ipt), or elaborate blain why the ite communication	e on the	nis item by providing not applicable/relevant
his" to indicate directed additional information for your study All available informa	et quotes fro on not in the ation on the	m your m ms, or bri ory, desig	nanuscr iefly exp gn and d	ipt), or elaborate plain why the ite	e on th	nis item by providing
his" to indicate directed additional information or your study All available informa	et quotes fro on not in the ation on the	m your m ms, or bri ory, desig	nanuscr iefly exp gn and d	ipt), or elaborate plain why the ite	e on th	nis item by providing
his" to indicate directed additional information or your study All available informa	et quotes fro on not in the ation on the	m your m ms, or bri ory, desig	nanuscr iefly exp gn and d	ipt), or elaborate plain why the ite	e on th	nis item by providing
his" to indicate directed additional information or your study All available informa	et quotes fro on not in the ation on the	m your m ms, or bri ory, desig	nanuscr iefly exp gn and d	ipt), or elaborate plain why the ite	e on th	nis item by providing
his" to indicate direc additional informatio or your study All available inform	et quotes fro on not in the ation on the	m your m ms, or bri ory, desig	nanuscr iefly exp gn and d	ipt), or elaborate plain why the ite	e on th	nis item by providing
his" to indicate directed indicate directed in the high results and the highest the highest results and the highest results are the highest results and the highest results are the highest results ar	t quotes fro	m your m	nanuscr	ipt), or elaborate	e on th	nis item by providing
		from the	o manu	script (include q		in augtotion morely "like
Does your paper ac	ldress subi	tem 5-vi	iii? *			
abitem not at an IIII	portant O					
ubitem not at all im	nortant O	0 0		) occoptici		
rages, presence of fi	1	2 3				
on presentation strated ages, presence of h	tegies [1], inc	luding pa	age des	ign principles, a		
communication deliv	ery channels	s and – if	f compu	iter-mediated co	mmu	nication is a component so includes information
	ether [and h	ow] it is t	ailored	to individual cir	cumst	ances and allows users
ehaviour change te	chniques, pe	rsuasive	feature	s, etc., see e.g.,	[7, 8] 1	for terminology). This oming from and who
Describe mode of de comparator, and the						intervention and structional strategy [1],
comparator, and th	e theoretic	al frame	work			
5-viii) Mada of dali	very featur	es/func	tionalit	ies/componer	te of	the intervention and
A powerpoint prese made available for				s nas been		

	<u> </u>
Clarify the level of human involvement Clarify the level of human involvement (care providers or hasistance) in the e-intervention or as co-intervention (deta rofessionals involved, if any, as well as "type of assistance of the support, how it is initiated, and the medium by which the necessary to distinguish between the level of human involvement required for a routine applications under item 21 – generalizability).	ail number and expertise of e offered, the timing and frequency the assistance is delivered". It may volvement required for the trial, and
1 2 3 4 5	
ubitem not at all important 🔘 🔘 🔘 🔘 essent	ial 
copy and paste relevant sections from the manuscript (includes in its indicate direct quotes from your manuscript), or eladitional information not in the ms, or briefly explain why or your study  For the intervention during the trial we needed a communication manager available 24/7 ICE. Technical support was available and the communication of	aborate on this item by providing the item is not applicable/relevant
	aborate on this item by providing the item is not applicable/relevant nity able of the item is not applicable of the item is not applicable.
copy and paste relevant sections from the manuscript (inchis" to indicate direct quotes from your manuscript), or eladditional information not in the ms, or briefly explain why or your study  For the intervention during the trial we needed a commur manager available 24/7 ICE. Technical support was avail by phone when needed (not needed except for essential system updates). Health professionals, being a GP, a psychologist, a sexuologist, a police agent and and expethe area of family violence were available for questions a guided chats (one session of 1-2 hours every twelve wee During the trial, a research assistant was available 8 hours.	aborate on this item by providing the item is not applicable/relevant with able able and for the item is not applicable/relevant with able able able able able able able able
Copy and paste relevant sections from the manuscript (inchis" to indicate direct quotes from your manuscript), or eladditional information not in the ms, or briefly explain why or your study  For the intervention during the trial we needed a commur manager available 24/7 ICE. Technical support was avail by phone when needed (not needed except for essential system updates). Health professionals, being a GP, a psychologist, a sexuologist, a police agent and and expethe area of family violence were available for questions a guided chats (one session of 1-2 hours every twelve weed During the trial, a research assistant was available 8 hours for any prompts/reminders used: Clarify if there were past of the application, what triggered them, frequence is the service of prompts/reminders requirements for a routine application outside of a Report any prompts for a routine applicatio	aborate on this item by providing the item is not applicable/relevant with able able and for the item is not applicable/relevant with able able able able able able able able

questionnaire. They receive	hey need to complete a		
i-xii) Describe any co-int describe any co-intervention rovided in addition to the to esigned as stand-alone int ecessary to distinguish be raining for a routine applicate eneralizability.	ns (incl. training/suppor argeted eHealth interve ervention. This includes tween the level of traini ation outside of a RCT s	rt): Clearly state an ntion, as ehealth i s training sessions ng required for the	ntervention may not be and support [1]. It may be trial, and the level of
	1 2 3 4 5		
ubitem not at all important	0 0 0 0 0	essential	
			,
5a) Completely	defined pre-	specified	nrimary and
secondary outowhen they were  Does your paper address Copy and paste relevant seconds:  to indicate direct quote additional information not information study	come measure assessed consort subitem 6 ctions from the manusces from your manuscrip	a? * cript (include quote t), or elaborate on	es in quotation marks "like this item by providing

If outcomes were obtained t	hrou	gh o	nline	· que	stior	naires were designed/deployed naires, describe if they were validated for now the questionnaires were
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address						
Copy and paste relevant sections Questionnaires were not spather researchers.						
		ow "	use'	' (ind	clud	ng intensity of use/dosage) was
defined/measured/monito Describe whether and how "u		(incl	udin	a int	oncit	v of use/desage) was
	d (lo	gins	, log	file a	naly	sis, etc.). Use/adoption metrics are
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address s Copy and paste relevant sec					orint	toyt
During the whole study per collected using Google and [45, 46].	iod,	quar	ntitat	ive u	sage	e data was
6a-iii) Describe whether, h obtained	iow,	and	who	en q	ualit	ative feedback from participants was
Describe whether, how, and which the second through emails, feedback for						ack from participants was obtained (e.g., groups).
,	1	2	3	4	5	
,						
subitem not at all important	0	0	0	0	0	essential

In this study, qualitative data was used to support and illustrate quantitative data. Qualitative data was collected from openended questions in questionnaires and from Community Managers diaries, including reports on their activities and actions[47-49].	^
	<b>&gt;</b>

## 6b) Any changes to trial outcomes after the trial commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

or your study	
under separate heading	^
	<b>\</b>
	<b>&gt;</b>

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

### 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 7a-i?

Yes, in the study protocol	^
	<b>V</b>
	<b>~</b>

## 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

or your orday	
not applicable	^
	<b>&gt;</b>

## 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, in the study protocol	^
	<b>&gt;</b>

## 8b) Type of randomisation; details of any restriction (such as blocking and block size)


#### Does your paper address CONSORT subitem 8b? \*

or your study	
Yes, in the study protocol	^
	<b>\</b>

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



# 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The allocation is carried out with help of a computer program by a research assistant.	^

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5

Dana 19	44 -	:o .					
<b>Does your paper address subite</b> Copy and paste relevant sections t			ecript (incl	nde anot	ee in a	uotation	marke "lik
this" to indicate direct quotes from additional information not in the motor for your study	your ma	anusc	ript), or ela	borate or	n this it	em by pro	oviding
no blinding except for questionna	ire data				^		
					<b>V</b>		
"intervention of interest" and wanformed consent procedures (4a-whether participants knew which it was the "comparator".	<b>hich on</b> ii) can cr nterventi	e was reate k ion wa	the "com piases and as the "inter	<b>parator"</b> certain e	xpecta	tions - dis	
"intervention of interest" and wanter intervention of interest" and wanter intervention of interest" and was the "comparator".	<b>hich on</b> e	e was reate k ion wa	the "com piases and as the "inter	<b>parator"</b> certain e	xpecta	tions - dis	
"intervention of interest" and walnformed consent procedures (4a- whether participants knew which i was the "comparator".	hich one ii) can cr nterventi 2 3	e was reate k ion wa	the "com plases and as the "inter	parator" certain e rvention	xpecta	tions - dis	
"intervention of interest" and wather participants knew which is was the "comparator".  1 subitem not at all important  Copy and paste relevant sections this to indicate direct quotes from additional information not in the manual information and was and was and was a section of the comparator.	hich one ii) can creater the content of the content	e was reate k ion wa  4  (ii? manu anusc	the "com plases and is the "inter complete the series of t	parator" certain e rvention o al ude quot borate or	xpecta of inter es in q n this it	tions - dis est" and uotation em by pro	which on marks "lik oviding
"intervention of interest" and we informed consent procedures (4a-whether participants knew which it was the "comparator".  1  Subitem not at all important   Does your paper address subited  Copy and paste relevant sections of this to indicate direct quotes from additional information not in the material  for your study	hich ond ii) can creater the content of the content	e was reate b ion wa  4  ii? manusc efly ex	the "com plases and is the "inter composition of the script (including plain why to	parator" certain e rvention o al ude quot borate or he item i	xpecta of inter es in q n this it	tions - dis est" and uotation em by pro	which on marks "lik oviding
11a-ii) Discuss e.g., whether pa "intervention of interest" and w Informed consent procedures (4a- whether participants knew which i was the "comparator".  1 subitem not at all important  Copy and paste relevant sections of this" to indicate direct quotes from additional information not in the m for your study  The control group was presented therefore the participants knew in they were allocated. While using ViBe, participants were not award allocation (access directly (interv	em 11a- from the a your mais, or brief the interes of each	e was reate k ion wa  4  ii? manuanusc efly ex aiting I group rvention othe	script (inclaint why to ist condition in which grown Feel the rs original	parator" certain e rvention o  al  ude quot borate or he item i  n, oup	xpecta of inter es in q n this it	tions - dis est" and uotation em by pro	which on marks "lik oviding
"intervention of interest" and wather participants knew which is was the "comparator".  1 subitem not at all important  Copy and paste relevant sections this to indicate direct quotes from additional information not in the mather for your study  The control group was presented therefore the participants knew in they were allocated. While using ViBe, participants were not aware.	em 11a- from the a your mais, or brief the interes of each	e was reate k ion wa  4  ii? manuanusc efly ex aiting I group rvention othe	script (inclaint why to ist condition in which grown Feel the rs original	parator" certain e rvention o  al  ude quot borate or he item i  n, oup	xpecta of inter es in q n this it	tions - dis est" and uotation em by pro	which on marks "lik oviding

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

oups viders or marks "like roviding e/relevant
viders or I marks "like roviding
viders or I marks "like roviding
ı marks "like roviding
ı marks "like roviding
roviding
roviding
ill use the
Specify hov ted in the
mputation
marks "like roviding
ioviuilly
e/relevant
וווו

## 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your pape	r address	CONSORT	subitem	12b? *
----------------	-----------	---------	---------	--------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

or your orang	
We used age sub-groups in the analysis of the data.	^
	<b>\</b>


# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

#### X26-i) Comment on ethics committee approval

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

Does your	· paper	address	subitem	X26-ii?
-----------	---------	---------	---------	---------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

On their first login, participants, and, for participants age 12 to 16, parents, gave informed consent electronically. Informed consent included stating name, place of residence and date of birth and clicking a approval button.

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Described in detail in the study protocol	^
	<b>\</b>

#### **RESULTS**

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

13b) For each group, losses and exclusions after randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram)*  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  o essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscrigelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after twelve weeks, after 24 weeks and after 36 weeks.	yes								
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important									
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important									
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important									
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important								$\vee$	
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important									
randomisation, together with reasons  Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important	10h)			L			د ما ما ما		-: <del></del>
Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks: this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/releva for your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival cur or other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscrip elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	,								sions after
CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/releval for your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicabe (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	randomisation,	to	ge	the	er v	wit	th reaso	ons	
CONSORT flow diagram) *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevator your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	_					_			
Copy and paste relevant sections from the manuscript (include quotes in quotation marks this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/releval for your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicabe (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after			ISOF	RT s	ubite	em 1	3b? (NOTE:	Prefe	rably, this is shown
this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/releval for your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicabe (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	,		s froi	m the	e ma	nusc	cript (include	quotes	s in quotation marks "l
for your study  Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival cur or other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important	this" to indicate direct quote	s fro	m yo	our m	nanu	scrip	ot), or elabora	ite on t	this item by providing
Yes, figure 1  13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain withe item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after		tne	ms,	or br	іетіу	expl	ain why the if	lem is	not applicable/relevar
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscripelaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	401 1) 4 1.1								
using the intervention/comparator in each group plotted over time, similar to a survival curror other figures or tables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important	,	~+++i+	iono	lioar	om (	0 0	proportion	fportio	inanta atill lagging in
subitem not at all important \( \) \( \) \( \) essential \( \) <b>Does your paper address subitem 13b-i?</b> Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	using the intervention/comp	arat	or in	each	n gro	ир р	lotted over ti	me, sin	
subitem not at all important \( \) \( \) \( \) essential \( \) <b>Does your paper address subitem 13b-i?</b> Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	<u> </u>						. 3.3	-	
Does your paper address subitem 13b-i?  Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscrip elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	essential		
Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscrip elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after									
Copy and paste relevant sections from the manuscript or cite the figure number if applicab (include quotes in quotation marks "like this" to indicate direct quotes from your manuscrip elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	Daga valle namae addes	ou.L:	<b>+</b> e = -	126	. :2				
(include quotes in quotation marks "like this" to indicate direct quotes from your manuscrip elaborate on this item by providing additional information not in the ms, or briefly explain we the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after						nuer	erint or cite th	ne fiauu	re number if applicable
the item is not applicable/relevant for your study  Figure 1 shows usage of the intervention at baseline, after	(include quotes in quotation	mar	ks "li	ike tł	nis" t	o inc	licate direct o	quotes	from your manuscript
Figure 1 shows usage of the intervention at baseline, after							mation not ir	the m	s, or briefly explain wh
							line after		
								^	

## 14a) Dates defining the periods of recruitment and follow-up

this" to indicate direct quot additional information not for your study	es from	our n	nanu	scrip	t), or elabo	rate on t	nis item l		
dates were given on inclu 2014)	sion (Jur	ne 1st	, 201	2 - Já	anuary 1st				
14a-i) Indicate if critical Indicate if critical "secular resources available or "cha	events" f	ell into	o the	stud	y period, e	g., signif	cant cha		ne
	1 2	3	4	5					
subitem not at all importar	t () (	) ()	$\bigcirc$	$\bigcirc$	essential				
<b>Does your paper address</b> Copy and paste relevant se				nusc	ript (includ	le quotes	in quota	ition marks "	ik
	ctions fr es from y n the ms luring the	om th our n , or br	e ma nanu: riefly venti	scrip expla on pe	t), or elaboain why the	rate on t	nis item l	by providing	
Copy and paste relevant sethis" to indicate direct quot additional information not for your study  No changes were made of participants completed the	ctions fr es from y n the ms luring the	om th our n , or br	e ma nanu: riefly venti	scrip expla on pe	t), or elaboain why the	rate on t	nis item l	by providing	
Copy and paste relevant sethis" to indicate direct quot additional information not for your study  No changes were made of participants completed the	rial e	om the your not not on the period of the per	e manuriefly ventieriod	or 1	was substitution with the way of the whole was substituted as the way of the	topp	ed (e	early)	nt

size was reached.

## 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

^
<u> </u>

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
this" to indicate direct quotes	tions s fro	s from	m the	e ma nanu	scrip	cript (include quotes in quotation marks "lik ot), or elaborate on this item by providing ain why the item is not applicable/relevant
for your study  User numbers and usage stable 2. Participants were a intent-to-treat, and not on u	tatis analy	tics a	are g	given	in fi	gure 1 and
	nten	t-to-t eats	reat,	sec this	onda	at ary analyses could include comparing only b longer a randomized sample (see 18-i).
subitem not at all important	0	0	0	0	0	essential
this" to indicate direct quotes	tions s fro the	s fror m yo ms, o	m the our m or br	e ma nanu iefly	scrip expl	cript (include quotes in quotation marks "lik ot), or elaborate on this item by providing ain why the item is not applicable/relevant y outcomes.
17a) For each p	rir	na	ry	an	d s	secondary outcome,

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing

Does your paper address CONSORT subitem 17a? \*

outcomes included 95%CI	or SI	) an	ıd p-	value	es.			
							<b>~</b>	
17a-i) Presentation of pro	cess	s out	tcon	nes	sucl	h as metric	s of use and int	ensity of use
In addition to primary/secon								-
such as metrics of use and i								
critical. This does not only re to more continuous exposur								
accompanied by a technical	desc	ripti	ion h					
after idle time) [1] (report un	der it	em (	6a).					
	1	2	3	4	5			
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$		essential		
						Coociitiai		
Copy and paste relevant sec this" to indicate direct quote additional information not in	tions s from the r	frorm yours, or was	m the our m or br	e manuriefly	scrip exp ed u	ot), or elabo lain why the	rate on this item	by providing
	tions s from the r	frorm yours, or was	m the our m or br	e manuriefly	scrip exp ed u	ot), or elabo lain why the	rate on this item	by providing
Copy and paste relevant sectifies to indicate direct quote additional information not infor your study  usage data and intensity or	tions s from the r	frorm yours, or was	m the our m or br	e manuriefly	scrip exp ed u	ot), or elabo lain why the	rate on this item	by providing
Copy and paste relevant sectifies to indicate direct quote additional information not infor your study  usage data and intensity of feasibility measures demandable.	tions s from the r f use nd an	t from your ms, or was and according to the control of the control	m thour moor br	e manu iefly ccuss tabili	ed u	ot), or elabo lain why the nder the	rate on this item item is not appli	oy providing cable/relevant
Copy and paste relevant sectifies to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demandation and the study of the	otions as from the restrictions of the restric	was	our m the our m or br	e manuiefly cuss tabili	expleed utty.	ot), or elabolain why the	rate on this item item is not application of	by providing cable/relevant
Copy and paste relevant sectifies to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demandation and the study of the	otions as from the restrictions of the restric	was	our m the our m or br	e manuiefly cuss tabili	expleed utty.	ot), or elabolain why the	rate on this item item is not application of	by providing cable/relevant
Copy and paste relevant sectifies to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demandable and reasonable and re	ou outline out	was	on the our more branches discovered on the control of the control	e manuriefly cuss tabili	ed u ty.	oresen	rate on this item item is not application of	by providing cable/relevant
Copy and paste relevant sectifies to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demandable and response to the company absolute and response your paper address	ou con	was ad acc	on the our more broad and the our more broad and the output of the outpu	e manuiefly cuss tabili	scripe expedu ty.	oresen Sizes	tation of is recomi	both mended
Copy and paste relevant sectifies to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the absolute and response your paper address.  Copy and paste relevant sectifies the control of the	ou constions	was ad acc	on the burn or broken sides of the company of the c	e manuiefly cuss tabili	scripe expleed uty.  S,	oresen Sizes  17b? * cript (include	tation of is recomi	both mended
Copy and paste relevant sectifis to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the absolute and respectively.  Does your paper address Copy and paste relevant sectifis to indicate direct quote additional information not in	ou elat constant	was ad acc	on the burn or broken sides of the burn or broken sides of the burn of the bur	e manuiefly cuss tabili	scripe expedu ty.  S,   ect	oresen Sizes Toby: * cript (included), or elabo	tation of is recommended is recommended in the state of the state on this item.	both mended
Copy and paste relevant sectifis to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the additional information not in for your study  17b) For binary absolute and respectively. The absolute and respectively and paste relevant sectifis to indicate direct quote additional information not infor your study.	ou elat constant	was ad acc	on the burn or broken sides of the burn or broken sides of the burn of the bur	e manuiefly cuss tabili	scripe expedu ty.  S,   ect	oresen Sizes Toby: * cript (included), or elabo	tation of is recommended is recommended in the state of the state on this item.	both mended
Copy and paste relevant sectifis to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the absolute and respectively.  Does your paper address Copy and paste relevant sectifis to indicate direct quote additional information not in	ou elat constant	was ad acc	on the burn or broken sides of the burn or broken sides of the burn of the bur	e manuiefly cuss tabili	scripe expedu ty.  S,   ect	oresen Sizes Toby: * cript (included), or elabo	tation of is recommended is recommended in the state of the state on this item.	both mended
Copy and paste relevant secthis" to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the state of t	ou etions of the r f use and an	was ad acc	on the burn or broken sides of the burn or broken sides of the burn of the bur	e manuiefly cuss tabili	scripe expedu ty.  S,   ect	oresen Sizes Toby: * cript (included), or elabo	tation of is recommended is recommended in the state of the state on this item.	both mended
Copy and paste relevant sectifis to indicate direct quote additional information not in for your study  usage data and intensity of feasibility measures demand the additional information not in for your study  17b) For binary absolute and respectively. The absolute and respectively and paste relevant sectifis to indicate direct quote additional information not infor your study.	ou etions of the r f use and an	was ad acc	on the burn or broken sides of the burn or broken sides of the burn of the bur	e manuiefly cuss tabili	scripe expedu ty.  S,   ect	oresen Sizes Toby: * cript (included), or elabo	tation of is recommended is recommended in the state of the state on this item.	both mended

# 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

#### Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

an exploratory analysis considering the T2-T3-T4 measurements of the control group as T0-T1-T2 using pre-post paired sample t-tests was added to explore any improvements on the primary outcomes in a larger sample size.

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

#### Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No analysis based on users only were performed

## 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

#### Does your paper address CONSORT subitem 19? \*

	~
	aches, technical problems
	echnical problems. This does not only include physical "harm" to ents such as perceived or real privacy breaches [1], technical
roblems, and other unexpo	ected/unintended incidents. "Unintended effects" also includes
inintended positive effects	[2].
	1 2 3 4 5
ubitem not at all importan	t O O O essential
Copy and paste relevant se	ctions from the manuscript (include quotes in quotation marks "like
Copy and paste relevant se his" to indicate direct quot	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing
Copy and paste relevant se his" to indicate direct quot idditional information not i or your study  there were no privacy bre except for the twitter news ViBe (outside the interver	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26
Copy and paste relevant se his" to indicate direct quot additional information not it or your study there were no privacy bre except for the twitter news	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26
Copy and paste relevant se his" to indicate direct quot additional information not is for your study  there were no privacy bre except for the twitter news ViBe (outside the interver)	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26
Copy and paste relevant se his" to indicate direct quot additional information not it for your study  there were no privacy bre except for the twitter news ViBe (outside the interver	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26
Copy and paste relevant se his" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter news ViBe (outside the interver hours due to a technical exception of the control	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26
Copy and paste relevant sethis" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter newsorial ViBe (outside the intervent hours due to a technical estaff/researchers	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, sefeed on the public part of Feel the tion part itself): it was down for 26 rror.  feedback from participants or observations from
Copy and paste relevant sethis" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter news ViBe (outside the interver hours due to a technical estaff/researchers nclude qualitative feedbace	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, sefeed on the public part of Feel the tion part itself): it was down for 26 irror.  feedback from participants or observations from k from participants or observations from staff/researchers, if
Copy and paste relevant se his" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter news ViBe (outside the interver hours due to a technical estaff/researchers nclude qualitative feedbace available, on strengths and	ctions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, sefeed on the public part of Feel the tion part itself): it was down for 26 rror.  feedback from participants or observations from
Copy and paste relevant se this" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter news ViBe (outside the interver hours due to a technical estaff/researchers nolude qualitative feedbacterials) include qualitative feedbacterials and unintended/unexpected eff	tions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, efeed on the public part of Feel the tion part itself): it was down for 26 irror.  feedback from participants or observations from k from participants or observations from staff/researchers, if shortcomings of the application, especially if they point to
this to indicate direct quot additional information not information not information information not information information not information not information information not in	retions from the manuscript (include quotes in quotation marks "like tes from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, as-feed on the public part of Feel the tion part itself): it was down for 26 irror.  If the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, as-feed on the public part of Feel the tion part itself): it was down for 26 irror.
Copy and paste relevant sethis" to indicate direct quot additional information not if or your study  there were no privacy bre except for the twitter news ViBe (outside the interver hours due to a technical estaff/researchers nclude qualitative feedbace available, on strengths and unintended/unexpected eff	retions from the manuscript (include quotes in quotation marks "like es from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant aches and no technical problems, s-feed on the public part of Feel the tion part itself): it was down for 26 irror.   **The providing of the application of the applicatio

Observations and qualitative feedback from Community managers on feasibility measures practicality and implementation were included. Qualitative efficacy and feedback was provided as support for quantitative efficacy.	^
	<b>V</b>

#### **DISCUSSION**

## 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

### 22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

	ı	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The demand for FtV was high. Acceptability, including satisfaction and safety, were good. FtV was perceived as helpful. However, the participation rate was rather low and no strict conclusions on efficacy could be drawn. In the following paragraphs we would like to highlight some of the most findings.

#### 22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing

potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important	included	
potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important		
potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important		
potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important		
subitem not at all important \( \cap \) \( \cap \) essential  Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability)  of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations		<b>∨</b>
potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important		
potential bias, imprecision, and, if relevant, multiplicity of analyses  20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important		
multiplicity of analyses  20-i) Typical limitations in ehealth trials:  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important	20) Trial limit	ations, addressing sources of
20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	potential bias	s, imprecision, and, if relevant,
20-i) Typical limitations in ehealth trials  Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important   essential  Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	•	
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important	marcipilotty of	i dilaly 500
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trial often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important	20-i) Typical limitation	ns in ehealth trials
non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.  1 2 3 4 5  subitem not at all important	Typical limitations in ehe	ealth trials: Participants in ehealth trials are rarely blinded. Ehealth tria
unexpected events.  1 2 3 4 5  subitem not at all important		
subitem not at all important \( \) \( \) \( \) essential \( \)  Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations		ion, asability issues, blases through mornied consent procedures,
Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations		1 2 3 4 5
Does your paper address subitem 20-i? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations		
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  21) Generalisability (external validity, applicability) yes  21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	subitem not at all import	tant O O O essential
21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant	sections from the manuscript (include quotes in quotation marks "like
21) Generalisability (external validity, applicability) of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information no	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
of the trial findings  NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing
NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant
patients, and care providers or centers involved in the trial  21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability)
21-i) Generalizability to other populations  Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings
Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin NPT: External validity of	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings of the trial findings according to the intervention, comparators,
Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin NPT: External validity of	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings of the trial findings according to the intervention, comparators,
applicability of the study results for other organizations	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin NPT: External validity of patients, and care prove	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings of the trial findings according to the intervention, comparators, viders or centers involved in the trial
1 2 3 4 5	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin NPT: External validity of patients, and care proven the content of the content of the trial for patients and care proven the content of the trial for patients and care proven the content of the trial for patients and care proven the content of the con	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing of in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings of the trial findings according to the intervention, comparators, viders or centers involved in the trial to other populations populations: In particular, discuss generalizability to a general
1 L U T U	Copy and paste relevant this" to indicate direct quadditional information not for your study  yes  21) Generalis of the trial fin NPT: External validity of patients, and care proven the company of the	sections from the manuscript (include quotes in quotation marks "like uotes from your manuscript), or elaborate on this item by providing ot in the ms, or briefly explain why the item is not applicable/relevant cability (external validity, applicability) adings of the trial findings according to the intervention, comparators, viders or centers involved in the trial to other populations populations: In particular, discuss generalizability to a general side of a RCT setting, and general patient population, including

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Feel the ViBe is general online available intervention. Adolescents and young adults can register from any location they like, only needing access to the internet. Consequently, participants registering online were geographically coming from a wide range of locations, not only in the Netherlands, but also from the Dutch speaking part of Belgium, Flanders. Patient characteristics ranged substantially even as the type of violence and the history of former healthcare.

### 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other cointerventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Results on adaptation were not included but can be obtained when needed form the researcher.

#### OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

This randomised feasibility study is conducted in the Netherlands, registered in The Netherlands National Trial Register (NTR) and assigned the trial ID NTR3692.

### 24) Where the full trial protocol can be accessed, if available

#### Does your paper address CONSORT subitem 24? \*


Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Trial registration
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3692
Study protocol
http://bmcpublichealth.biomedcentral.com/articles/10.1186/147
1-2458-13-226

## 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



### X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

Does your paper address subitem X27-i?	
Copy and paste relevant sections from the manuscript (inc this" to indicate direct quotes from your manuscript), or ela additional information not in the ms, or briefly explain why for your study	aborate on this item by providing
yes	
	<b>&gt;</b>
About the CONSORT EHEALTH	checklist
As a result of using this checklist, did you make chan	ges in your manuscript? *
o yes, major changes	
<ul><li>yes, minor changes</li></ul>	
○ no	
What were the most important changes you made as	a result of using this checklist?
We included more data from the study protocol to make the	
article more readable for the readers.	^
	<b>V</b>
How much time did you spend on going through the c	hecklist INCLUDING making
changes in your manuscript *	
8	
As a recult of using this shooklist, do you think your	nanusarint has impressed? *
As a result of using this checklist, do you think your n	nanuscript nas improved? ^
<ul><li>yes</li></ul>	
○ no	
Other:	
Would you like to become involved in the CONSORT E	HEALTH group?
-	
Would you like to become involved in the CONSORT E This would involve for example becoming involved in partic "Explanation and Elaboration" document	

I spend a lot of time completing thi disappointment and shock the resi too long answers! I removed most difficulties. I find it strange that the given beforehand!	ults could no be saved due to of it, but I am still having
STOD - Sava this for	rm as DDE before you click
submit	rm as PDF before you click
	ed in this form, we recommend to generate a PDF of t "print" and then select "print as PDF") before you
When you submit your (revised) p	paper to JMIR, please upload the PDF as supplementary
Don't worry if some text in the tex information in our database. That	ktboxes is cut off, as we still have the complete nk you!
Final step: Click sub	omit!
Click submit so we have your ans	swers in our database!
Submit	
Never submit passwords through G	oogle Forms.